As major pharmaceutical companies face billions in potential revenue losses from expiring patents, smaller biotechnology firms could become increasingly attractive acquisition targets.
The biotechnology sector could be approaching another wave of merger and acquisition activity as major pharmaceutical companies confront a growing challenge: the expiration of patent protection on blockbuster medications. With an estimated $300 billion to $400 billion in pharmaceutical revenue facing patent-related pressure beginning in 2028, large drugmakers are increasingly focused on replenishing their development pipelines, potentially creating opportunities for smaller biotechnology companies.
The industry’s so-called “patent cliff” occurs when branded medications lose market exclusivity, allowing generic or biosimilar competitors to enter the market. These alternatives can rapidly erode sales, forcing pharmaceutical manufacturers to identify new sources of revenue.
For small-cap biotechnology investors, this dynamic could become an important catalyst for dealmaking.
Pharmaceutical companies have several options for replacing revenue from aging products, including internal research, licensing agreements, strategic partnerships, and acquisitions. Purchasing smaller biotechnology companies with promising clinical assets can provide access to new treatments without starting development programs from scratch.
Merger and acquisition activity across the pharmaceutical and life sciences sectors continues to reflect growing demand for innovative treatments and promising drug development pipelines. Oncology, immunology, rare diseases, and other specialized therapeutic areas remain key areas of strategic interest as major pharmaceutical companies seek new opportunities for long-term growth.
Among emerging biotechnology companies advancing treatments in these fields is Cardiff Oncology (NASDAQ: CRDF), which is developing onvansertib, a PLK1 inhibitor being studied in combination with standard therapies for metastatic colorectal cancer. The company reported encouraging Phase 2 results and has outlined plans for a registrational trial, subject to additional financing.
Such programs illustrate the type of clinical innovation occurring across the smaller biotechnology sector.
Biotechnology companies frequently operate without commercial revenue, relying on capital markets to finance expensive clinical trials and regulatory development.
This funding environment can make partnerships particularly valuable.
Ocugen (NASDAQ: OCGN), which is developing gene therapies targeting inherited retinal diseases, has pursued regional licensing opportunities as part of its broader development strategy. Such arrangements demonstrate how smaller biotechnology companies can access additional resources while retaining certain commercial rights.
Meanwhile, Eledon Pharmaceuticals (NASDAQ: ELDN) is developing therapies involving immune modulation, including tegoprubart, an investigational treatment being studied in kidney transplantation.
These companies represent different approaches to addressing significant medical needs, highlighting the range of assets that larger pharmaceutical companies may evaluate when expanding their portfolios.
Their inclusion does not imply that acquisition discussions are underway.
Although pharmaceutical patent expirations create incentives for acquisitions, clinical progress remains central to company valuations.
Investors should monitor trial results, regulatory milestones, cash reserves, intellectual property protection, and licensing announcements. Companies approaching pivotal clinical milestones may attract greater strategic attention, but they also face substantial development risks.
Another consideration is whether pharmaceutical buyers favor outright acquisitions or licensing agreements that provide access to promising treatments without assuming full development costs.
Following a slowdown in biotechnology dealmaking over the summer, industry observers anticipate renewed acquisition interest as companies prepare for upcoming patent expirations.
For investors following the small-cap biotechnology sector, the implications extend beyond potential takeover premiums. Increased dealmaking could improve sentiment, provide additional financing opportunities, and establish valuation benchmarks for emerging therapeutic platforms.
As the pharmaceutical industry prepares for significant revenue losses from patent expirations, innovative smaller biotechnology companies could play an increasingly important role in shaping the next generation of treatments.
